\sim	\cap	\cap	1	\sim		1
S-	U	9	4	/.	_	- 1

1415

1617

18

SENATE BILL 5719

State of Washington 66th Legislature

2019 Regular Session

By Senators Hasegawa and Conway

- AN ACT Relating to hemp production; amending RCW 69.50.204; reenacting and amending RCW 69.50.101; adding a new section to chapter 15.120 RCW; adding a new chapter to Title 15 RCW; repealing RCW 15.120.005, 15.120.010, 15.120.020, 15.120.030, 15.120.035, 15.120.040, 15.120.050, and 15.120.060; making an appropriation; providing an effective date; providing an expiration date; and declaring an emergency.
- 8 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:
- 9 <u>NEW SECTION.</u> **Sec. 1.** The legislature intends to:
- 10 (1) Authorize and establish a new licensing and regulatory 11 program for hemp production in this state in accordance with the 12 agricultural improvement act of 2018, P.L. 115-334;
 - (2) Replace the industrial hemp research program in chapter 15.120 RCW, with the new licensing and regulatory program established in this chapter, and enable hemp growers licensed under the industrial research program on the effective date of rules implementing this chapter and regulating hemp production, to transfer into the program created in this chapter; and
- 19 (3) Authorize the growing of hemp as a legal, agricultural 20 activity in this state. Hemp is an agricultural product that may be 21 legally grown, produced, processed, possessed, transferred,

p. 1 SB 5719

- commercially sold, and traded. Hemp and hemp products produced in accordance with this chapter may be transferred and sold within the state, outside of this state, and internationally. Nothing in this chapter is intended to prevent or restrain commerce in this state involving hemp or hemp products produced lawfully under the laws of
- NEW SECTION. Sec. 2. The definitions in this section apply throughout this chapter unless the context clearly requires otherwise.
- 10 (1) "CBD" means cannabidiol.

another state or country.

6

11

17

18

1920

2122

23

- (2) "CBD product" has the same meaning as in RCW 69.50.101.
- 12 (3) "Crop" means hemp grown as an agricultural commodity.
- 13 (4) "Cultivar" means a variation of the plant *Cannabis sativa L.*14 that has been developed through cultivation by selective breeding.
- 15 (5) "Department" means the Washington state department of 16 agriculture.
 - (6) "Food" means articles used for food or drink for human consumption or food for animals.
 - (7) "Hemp" means the plant *Cannabis sativa L.* and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis.
- 24 (8) "Postharvest test" means a test of delta-9 25 tetrahydrocannabinol concentration levels of hemp after harvested 26 based on ground whole plant samples without heat applied.
- 27 (9) "Process" means the processing, compounding, or conversion of 28 hemp into hemp commodities or products.
- 29 (10) "Produce" means the planting, cultivation, growing, or 30 harvesting of hemp including hemp seed.
- NEW SECTION. Sec. 3. (1) The department must develop an agricultural commodity program to replace the industrial hemp research pilot program in chapter 15.120 RCW, in accordance with the agricultural improvement act of 2018, P.L. 115-334.
- 35 (2) The department has sole regulatory authority over the 36 production of hemp and may adopt rules to implement this chapter. All 37 rules relating to hemp, including any testing of hemp, are outside of 38 the control and authority of the liquor and cannabis board.

p. 2 SB 5719

(3) If the department adopts rules implementing this chapter that are effective by June 1, 2019, people licensed to grow hemp under chapter 15.120 RCW may transfer into the regulatory program established in this chapter, and continue hemp production under this chapter. If the department adopts rules implementing this chapter that are effective after June 1, 2019, people licensed to grow hemp under chapter 15.120 RCW may continue hemp production under this chapter as of the effective date of the rules.

- 9 <u>NEW SECTION.</u> **Sec. 4.** (1) The department must develop a proposal outlining the state's plan for regulating hemp production in accordance with this chapter and the agricultural improvement act of 2018, P.L. 115-334.
- 13 (2) The proposal for the state's plan must include the following 14 requirements and components:
 - (a) A practice for hemp producers to maintain relevant information regarding land on which hemp is produced including a legal description of the land, for a period of not less than three calendar years;
 - (b) A procedure for testing, using post-decarboxylation or other similarly reliable methods, delta-9 tetrahydrocannabinol concentration levels of hemp, without the application of heat;
 - (c) A procedure for the effective disposal of plants, whether growing or not, that are produced in violation of this chapter, and products derived from such plants;
 - (d) Procedures for enforcement required under the agricultural improvement act of 2018, P.L. 115-334, including a process for licensees to comply with this chapter through a corrective action plan in appropriate circumstances;
 - (e) A procedure for conducting annual inspections of, at a minimum, a random sample of hemp producers to verify hemp is not produced in violation of this chapter;
 - (f) A procedure for obtaining and submitting the information described in section 297C(d)(2) of the agricultural improvement act of 2018, P.L. 115-334, as applicable, to the secretary of the United States department of agriculture not more than thirty days after the date on which the information is received; and
- 37 (g) A certification that the state has the resources and 38 personnel to carry out the practices and procedures described in this 39 section.

p. 3 SB 5719

- 1 (3) The proposal for the state's plan may include any other 2 practice or procedure established to the extent the practice or 3 procedure is consistent with the agricultural improvement act of 4 2018, P.L. 115-334.
- NEW SECTION. Sec. 5. The department must develop a post harvest test protocol for testing hemp under this chapter that includes testing of whole plant samples.
- 8 <u>NEW SECTION.</u> **Sec. 6.** CBD and CBD products derived from hemp are considered a food product that must be tested and treated in accordance with other agricultural crop derived food products for human and animal consumption.
- NEW SECTION. Sec. 7. (1) There is a hemp producer license issued by the department to applicants qualified under this chapter and the agricultural improvement act of 2018, P.L. 115-334.
- 15 (2) The department must establish license fees in an amount that 16 will fund the implementation of this chapter and sustain the hemp 17 program. License fees and any money received by the department under 18 this chapter must be deposited in the hemp regulatory account created 19 in section 9 of this act.
- Sec. 8. (1) The hemp authorized for production 20 NEW SECTION. 21 under this chapter must be propagated through certified, 22 conventionally bred pedigreed seeds as determined by the department through its rule-making authority and as provided in this section. 23 24 Except when grown by an accredited agricultural research institution 25 or by a registered seed breeder developing a new Washington seed cultivar, hemp must be grown only from seed types identified in 26 27 subsection (2) of this section or identified on a list of approved 28 seed cultivars to be established by the department by rule.
 - (2) The following varieties of seed cultivars are deemed approved for hemp production: Alyssa; Anka; CFX-1; CFX-2; Delores; X-59 (Hemp Nut); Crag; CRS-1; USO 14; USO 31; and Zolotonosha 11.

30

3132

33

3435

36

(3) Except as provided in subsection (5) of this section, the following varieties of seed cultivars are deemed approved for hemp production but must undergo THC testing unless and until such time as the department determines they are exempt from THC testing: Canda; CanMa; Carmagnola; Carmen; CS; Deni; Epsilon 68; ESTA-1; Fasamo;

p. 4 SB 5719

- 1 Fedrina 74; Fedura 17; Felina 34; Ferimon; Fibranova; Fibriko;
- 2 Fibrimon 24; Fibrimon 56; Finola; Futura 75; Joey; Jutta; Komplti;
- 3 Kompolti Hybrid TC; Kompolti Sargaszaru; Lovrin 110; Petera; Santhica
- 4 27; Silesia; UC-RGM; Uniko B; Yvonne; and Zolotonosha 15.

18

19

2021

22

23

2425

26

2728

29

30 31

32

33

34

3536

37

38

- 5 (4) In addition to those approved cultivars identified in 6 subsections (2) and (3) of this section, the department must 7 determine and adopt by rule a list of approved seed cultivars. In 8 establishing the list of department-approved seed cultivars, the 9 department should consider the following:
- 10 (a) Hemp seed cultivars that have been certified after December 11 31, 2012, by member organizations of the association of official seed 12 certifying agencies, including, but not limited to, the Canadian seed 13 growers' association; and
- 14 (b) Hemp seed cultivars that have been certified after December 15 31, 2012, by the organization of economic cooperation and development.
 - (5) In addition to the hemp seed cultivars identified in subsections (2), (3), and (4) of this section, until January 1, 2022, a licensed hemp producer may produce hemp from any cultivar brought into this state that has planting, growth, and stability records covering at least three years. Any such cultivar is deemed approved for planting.
 - (6) Hemp seeds are subject to the provisions and requirements of RCW 15.49.370, which establishes the general regulatory authority of the department with respect to agricultural seeds. Under this authority, the department may sample, inspect, analyze, and generally regulate the hemp seeds used by licensed growers in this state. The department may also charge fees and special assessments to licensed growers, as established by rule, related to the inspection, testing, and certification of hemp seeds.
 - (7) For the purposes of this chapter and RCW 15.49.370, hemp seed samples collected for inspection and testing purposes must be directly taken into the custody of an authorized employee of the department. Following collection, the department employee must package and transport the seeds in a manner that ensures that the integrity of the sample is maintained until delivery to the testing facility.
 - (8) The department is not responsible for:
- 39 (a) Determining whether a specific hemp product has been derived 40 from approved hemp cultivars; or

p. 5 SB 5719

- 1 (b) Taking any enforcement action requiring the determination of 2 whether a hemp product has been derived from approved hemp cultivars.
- NEW SECTION. Sec. 9. The hemp regulatory account is created in the custody of the state treasurer. All receipts from licensing fees established under this chapter must be deposited into the account.
- 6 Expenditures from the account may be used only for implementing this
- 7 chapter. Only the director of the state department of agriculture or
- 8 the director's designee may authorize expenditures from the account.
- 9 The account is subject to allotment procedures under chapter 43.88
- 10 RCW, but an appropriation is not required for expenditures.
- NEW SECTION. Sec. 10. The department must develop and make accessible an internet-based application designed to assist hemp
- 13 producers by providing regional communications concerning recommended
- 14 planting times for hemp crops in this state.
- 15 NEW SECTION. Sec. 11. In an effort to prevent cross-pollination 16 between hemp plants produced under this chapter and marijuana plants produced under chapter 69.50 RCW, the department, in consultation 17 with the liquor and cannabis board, must review the state's policy 18 19 regarding cross-pollination and pollen capture to appropriate policy is in place, and must modify policies or establish 20 new policies as appropriate. Under any such policy, when a documented 21 22 conflict involving cross-pollination exists between two farms or 23 production facilities growing or producing hemp or marijuana, the farm or production facility operating first in time shall have the 24 25 right to continue operating and the farm or production facility 26 operating second in time must cease growing or producing hemp or marijuana, as applicable. 27
- NEW SECTION. Sec. 12. (1)(a) A legislative task force on the availability of crop insurance for hemp producers is established, with members as provided in this subsection.
- 31 (i) The president of the senate shall appoint one member from 32 each of the two largest caucuses of the senate.
- (ii) The speaker of the house of representatives shall appoint one member from each of the two largest caucuses of the house of representatives.

p. 6 SB 5719

- (iii) The president of the senate and the speaker of the house of representatives shall jointly appoint the following members:
 - (A) One member who is a representative of the farm services agency within the United States department of agriculture;
 - (B) One member who is a representative of the risk management agency within the United States department of agriculture;
 - (C) One member who represents the Washington state department of agriculture;
- 9 (D) One member who represents a state farm bureau within the 10 state; and
 - (E) One member who represents the hemp industry.

- (b) The task force must choose its chair from among its legislative membership. A member appointed under (a)(i) or (ii) of this subsection (1) must convene the initial meeting of the task force.
- (2) The task force must review the following issue: Ensuring crop insurance is available in this state for hemp producers so hemp production can be expeditiously and successfully integrated into this state's economy and people in this state can take full advantage of the agricultural and economic opportunities created for hemp production and commerce in the agriculture improvement act of 2018, P.L. 115-334.
- (3) Staff support for the task force must be provided by the house of representatives office of program research and the senate committee services.
 - (4) Legislative members of the task force are reimbursed for travel expenses in accordance with RCW 44.04.120. Nonlegislative members are not entitled to be reimbursed for travel expenses if they are elected officials or are participating on behalf of an employer, governmental entity, or other organization. Any reimbursement for other nonlegislative members is subject to chapter 43.03 RCW.
 - (5) The expenses of the task force must be paid jointly by the senate and the house of representatives. Task force expenditures are subject to approval by the senate facilities and operations committee and the house of representatives executive rules committee, or their successor committees.
- 37 (6) The task force shall report its findings and recommendations 38 to the speaker of the house of representatives, the president of the 39 senate, the governor, and the appropriate committees of the 40 legislature by December 1, 2020.

p. 7 SB 5719

(7) This section expires June 30, 2021.

1

2324

25

26

- NEW SECTION. Sec. 13. A new section is added to chapter 15.120 RCW to read as follows:
- 4 (1) On the effective date of rules adopted by the department regulating hemp production under chapter 15.--- RCW (the new chapter created in section 18 of this act), a licensed hemp grower under this chapter may immediately produce hemp pursuant to chapter 15.--- RCW (the new chapter created in section 18 of this act) with all the privileges of a hemp producer licensed under chapter 15.--- RCW (the new chapter created in section 18 of this act).
- 11 (2) This section expires January 1, 2020.
- Sec. 14. RCW 69.50.101 and 2018 c 132 s 2 are each reenacted and amended to read as follows:
- The definitions in this section apply throughout this chapter unless the context clearly requires otherwise.
- 16 (a) "Administer" means to apply a controlled substance, whether 17 by injection, inhalation, ingestion, or any other means, directly to 18 the body of a patient or research subject by:
- 19 (1) a practitioner authorized to prescribe (or, by the 20 practitioner's authorized agent); or
- 21 (2) the patient or research subject at the direction and in the 22 presence of the practitioner.
 - (b) "Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser. It does not include a common or contract carrier, public warehouseperson, or employee of the carrier or warehouseperson.
- (c) "CBD concentration" has the meaning provided in RCW 69.51A.010.
- 29 (d) "CBD product" means any product containing or consisting of 30 cannabidiol.
- 31 (e) "Commission" means the pharmacy quality assurance commission.
- 32 (f) "Controlled substance" means a drug, substance, or immediate 33 precursor included in Schedules I through V as set forth in federal 34 or state laws, or federal or commission rules, but does not include 35 hemp as defined in section 2 of this act or industrial hemp as 36 defined in RCW 15.120.010.

p. 8 SB 5719

- (g) (1) "Controlled substance analog" means a substance the chemical structure of which is substantially similar to the chemical structure of a controlled substance in Schedule I or II and:
- 4 (i) that has a stimulant, depressant, or hallucinogenic effect on 5 the central nervous system substantially similar to the stimulant, 6 depressant, or hallucinogenic effect on the central nervous system of 7 a controlled substance included in Schedule I or II; or
 - (ii) with respect to a particular individual, that the individual represents or intends to have a stimulant, depressant, or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance included in Schedule I or II.
 - (2) The term does not include:
 - (i) a controlled substance;

2

3

8

10 11

12

13

14

15

26

27

2829

37

- 16 (ii) a substance for which there is an approved new drug 17 application;
- (iii) a substance with respect to which an exemption is in effect for investigational use by a particular person under Section 505 of the federal food, drug, and cosmetic act, 21 U.S.C. Sec. 355, or chapter 69.77 RCW to the extent conduct with respect to the substance is pursuant to the exemption; or
- (iv) any substance to the extent not intended for human consumption before an exemption takes effect with respect to the substance.
 - (h) "Deliver" or "delivery" means the actual or constructive transfer from one person to another of a substance, whether or not there is an agency relationship.
 - (i) "Department" means the department of health.
- 30 (j) "Designated provider" has the meaning provided in RCW 31 69.51A.010.
- 32 (k) "Dispense" means the interpretation of a prescription or 33 order for a controlled substance and, pursuant to that prescription 34 or order, the proper selection, measuring, compounding, labeling, or 35 packaging necessary to prepare that prescription or order for 36 delivery.
 - (1) "Dispenser" means a practitioner who dispenses.
- 38 (m) "Distribute" means to deliver other than by administering or 39 dispensing a controlled substance.
- 40 (n) "Distributor" means a person who distributes.

p. 9 SB 5719

(o) "Drug" means (1) a controlled substance recognized as a drug in the official United States pharmacopoeia/national formulary or the official homeopathic pharmacopoeia of the United States, or any supplement to them; (2) controlled substances intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in individuals or animals; (3) controlled substances (other than food) intended to affect the structure or any function of the body of individuals or animals; and (4) controlled substances intended for use as a component of any article specified in (1), (2), or (3) of this subsection. The term does not include devices or their components, parts, or accessories.

- (p) "Drug enforcement administration" means the drug enforcement administration in the United States Department of Justice, or its successor agency.
- (q) "Electronic communication of prescription information" means the transmission of a prescription or refill authorization for a drug of a practitioner using computer systems. The term does not include a prescription or refill authorization verbally transmitted by telephone nor a facsimile manually signed by the practitioner.
- (r) "Immature plant or clone" means a plant or clone that has no flowers, is less than twelve inches in height, and is less than twelve inches in diameter.
 - (s) "Immediate precursor" means a substance:
- (1) that the commission has found to be and by rule designates as being the principal compound commonly used, or produced primarily for use, in the manufacture of a controlled substance;
- (2) that is an immediate chemical intermediary used or likely to be used in the manufacture of a controlled substance; and
- 29 (3) the control of which is necessary to prevent, curtail, or 30 limit the manufacture of the controlled substance.
 - (t) "Isomer" means an optical isomer, but in subsection (ff) (5) of this section, RCW 69.50.204(a) (12) and (34), and 69.50.206(b) (4), the term includes any geometrical isomer; in RCW 69.50.204(a) (8) and (42), and 69.50.210(c) the term includes any positional isomer; and in RCW 69.50.204(a) (35), 69.50.204(c), and 69.50.208(a) the term includes any positional or geometric isomer.
- 37 (u) "Lot" means a definite quantity of marijuana, marijuana 38 concentrates, useable marijuana, or marijuana-infused product 39 identified by a lot number, every portion or package of which is

p. 10 SB 5719

1 uniform within recognized tolerances for the factors that appear in 2 the labeling.

- (v) "Lot number" must identify the licensee by business or trade name and Washington state unified business identifier number, and the date of harvest or processing for each lot of marijuana, marijuana concentrates, useable marijuana, or marijuana-infused product.
- (w) "Manufacture" means the production, preparation, propagation, compounding, conversion, or processing of a controlled substance, either directly or indirectly or by extraction from substances of natural origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, and includes any packaging or repackaging of the substance or labeling or relabeling of its container. The term does not include the preparation, compounding, packaging, repackaging, labeling, or relabeling of a controlled substance:
- (1) by a practitioner as an incident to the practitioner's administering or dispensing of a controlled substance in the course of the practitioner's professional practice; or
- (2) by a practitioner, or by the practitioner's authorized agent under the practitioner's supervision, for the purpose of, or as an incident to, research, teaching, or chemical analysis and not for sale.
- (x) "Marijuana" or "marihuana" means all parts of the plant Cannabis, whether growing or not, with a THC concentration greater than 0.3 percent on a dry weight basis; the seeds thereof; the resin extracted from any part of the plant; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seeds or resin. The term does not include:
- (1) The mature stalks of the plant, fiber produced from the stalks, oil or cake made from the seeds of the plant, any other compound, manufacture, salt, derivative, mixture, or preparation of the mature stalks (except the resin extracted therefrom), fiber, oil, or cake, or the sterilized seed of the plant which is incapable of germination; or
- 35 (2) Hemp as defined in section 2 of this act, seeds used for
 36 licensed hemp production under chapter 15.--- RCW (the new chapter
 37 created in section 18 of this act), or industrial hemp as defined in
 38 RCW 15.120.010.

p. 11 SB 5719

(y) "Marijuana concentrates" means products consisting wholly or in part of the resin extracted from any part of the plant *Cannabis* and having a THC concentration greater than ten percent.

- (z) "Marijuana processor" means a person licensed by the state liquor and cannabis board to process marijuana into marijuana concentrates, useable marijuana, and marijuana-infused products, package and label marijuana concentrates, useable marijuana, and marijuana-infused products for sale in retail outlets, and sell marijuana concentrates, useable marijuana, and marijuana-infused products at wholesale to marijuana retailers.
- (aa) "Marijuana producer" means a person licensed by the state liquor and cannabis board to produce and sell marijuana at wholesale to marijuana processors and other marijuana producers.
- (bb) "Marijuana products" means useable marijuana, marijuana concentrates, and marijuana-infused products as defined in this section.
- (cc) "Marijuana researcher" means a person licensed by the state liquor and cannabis board to produce, process, and possess marijuana for the purposes of conducting research on marijuana and marijuanaderived drug products.
- (dd) "Marijuana retailer" means a person licensed by the state liquor and cannabis board to sell marijuana concentrates, useable marijuana, and marijuana-infused products in a retail outlet.
- (ee) "Marijuana-infused products" means products that contain marijuana or marijuana extracts, are intended for human use, are derived from marijuana as defined in subsection (x) of this section, and have a THC concentration no greater than ten percent. The term "marijuana-infused products" does not include either useable marijuana or marijuana concentrates.
- (ff) "Narcotic drug" means any of the following, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:
- (1) Opium, opium derivative, and any derivative of opium or opium derivative, including their salts, isomers, and salts of isomers, whenever the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation. The term does not include the isoquinoline alkaloids of opium.
- (2) Synthetic opiate and any derivative of synthetic opiate, including their isomers, esters, ethers, salts, and salts of isomers,

p. 12 SB 5719

- esters, and ethers, whenever the existence of the isomers, esters, ethers, and salts is possible within the specific chemical designation.
 - (3) Poppy straw and concentrate of poppy straw.
 - (4) Coca leaves, except coca leaves and extracts of coca leaves from which cocaine, ecgonine, and derivatives or ecgonine or their salts have been removed.
 - (5) Cocaine, or any salt, isomer, or salt of isomer thereof.
- 9 (6) Cocaine base.

5

6 7

8

14

1516

17

1819

20

2122

25

26

2728

29

32

- 10 (7) Ecgonine, or any derivative, salt, isomer, or salt of isomer 11 thereof.
- 12 (8) Any compound, mixture, or preparation containing any quantity 13 of any substance referred to in subparagraphs (1) through (7).
 - (gg) "Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction-sustaining liability. The term includes opium, substances derived from opium (opium derivatives), and synthetic opiates. The term does not include, unless specifically designated as controlled under RCW 69.50.201, the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). The term includes the racemic and levorotatory forms of dextromethorphan.
- 23 (hh) "Opium poppy" means the plant of the species Papaver 24 somniferum L., except its seeds.
 - (ii) "Person" means individual, corporation, business trust, estate, trust, partnership, association, joint venture, government, governmental subdivision or agency, or any other legal or commercial entity.
 - (jj) "Plant" has the meaning provided in RCW 69.51A.010.
- 30 (kk) "Poppy straw" means all parts, except the seeds, of the 31 opium poppy, after mowing.
 - (11) "Practitioner" means:
- 33 (1) A physician under chapter 18.71 RCW; a physician assistant under chapter 18.71A RCW; an osteopathic physician and surgeon under 34 chapter 18.57 RCW; an osteopathic physician assistant under chapter 35 18.57A RCW who is licensed under RCW 18.57A.020 subject to any 36 limitations in RCW 18.57A.040; an optometrist licensed under chapter 37 18.53 RCW who is certified by the optometry board under RCW 18.53.010 38 39 subject to any limitations in RCW 18.53.010; a dentist under chapter 40 18.32 RCW; a podiatric physician and surgeon under chapter 18.22 RCW;

p. 13 SB 5719

1 a veterinarian under chapter 18.92 RCW; a registered nurse, advanced registered nurse practitioner, or licensed practical nurse under 2 chapter 18.79 RCW; a naturopathic physician under chapter 18.36A RCW 3 who is licensed under RCW 18.36A.030 subject to any limitations in 4 RCW 18.36A.040; a pharmacist under chapter 18.64 RCW or a scientific 5 6 investigator under this chapter, licensed, registered or otherwise permitted insofar as is consistent with those licensing laws to 7 distribute, dispense, conduct research with respect to or administer 8 a controlled substance in the course of their professional practice 9 or research in this state. 10

(2) A pharmacy, hospital or other institution licensed, registered, or otherwise permitted to distribute, dispense, conduct research with respect to or to administer a controlled substance in the course of professional practice or research in this state.

1112

13

14

1516

17

18

19

20

2122

23

2425

26

27

28

29

- (3) A physician licensed to practice medicine and surgery, a physician licensed to practice osteopathic medicine and surgery, a dentist licensed to practice dentistry, a podiatric physician and surgeon licensed to practice podiatric medicine and surgery, a licensed physician assistant or a licensed osteopathic physician assistant specifically approved to prescribe controlled substances by his or her state's medical quality assurance commission or equivalent and his or her supervising physician, an advanced registered nurse practitioner licensed to prescribe controlled substances, or a veterinarian licensed to practice veterinary medicine in any state of the United States.
- (mm) "Prescription" means an order for controlled substances issued by a practitioner duly authorized by law or rule in the state of Washington to prescribe controlled substances within the scope of his or her professional practice for a legitimate medical purpose.
- 30 (nn) "Production" includes the manufacturing, planting, 31 cultivating, growing, or harvesting of a controlled substance.
- 32 (oo) "Qualifying patient" has the meaning provided in RCW 33 69.51A.010.
- 34 (pp) "Recognition card" has the meaning provided in RCW 35 69.51A.010.
- 36 (qq) "Retail outlet" means a location licensed by the state 37 liquor and cannabis board for the retail sale of marijuana 38 concentrates, useable marijuana, and marijuana-infused products.
- (rr) "Secretary" means the secretary of health or the secretary's designee.

p. 14 SB 5719

- 1 (ss) "State," unless the context otherwise requires, means a 2 state of the United States, the District of Columbia, the 3 Commonwealth of Puerto Rico, or a territory or insular possession 4 subject to the jurisdiction of the United States.
- 5 (tt) "THC concentration" means percent of delta-9
 6 tetrahydrocannabinol content per dry weight of any part of the plant
 7 Cannabis, or per volume or weight of marijuana product, or the
 8 combined percent of delta-9 tetrahydrocannabinol and
 9 tetrahydrocannabinolic acid in any part of the plant Cannabis
 10 regardless of moisture content.
- (uu) "Ultimate user" means an individual who lawfully possesses a controlled substance for the individual's own use or for the use of a member of the individual's household or for administering to an animal owned by the individual or by a member of the individual's household.
- 16 (vv) "Useable marijuana" means dried marijuana flowers. The term 17 "useable marijuana" does not include either marijuana-infused 18 products or marijuana concentrates.
- 19 **Sec. 15.** RCW 69.50.204 and 2015 2nd sp.s. c 4 s 1203 are each 20 amended to read as follows:

Unless specifically excepted by state or federal law or regulation or more specifically included in another schedule, the following controlled substances are listed in Schedule I:

- (a) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation:
- 28 (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-29 piperidinyl]-N-phenylacetamide);
 - (2) Acetylmethadol;
 - (3) Allylprodine;

21

22

23

2425

2627

30

31

34

- 32 (4) Alphacetylmethadol, except levo-alphacetylmethadol, also 33 known as levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;
 - (5) Alphameprodine;
- 35 (6) Alphamethadol;
- 36 (7) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)
- 37 ethyl-4-piperidyl] propionanilide); (1-(1-methyl-2-phenylethyl)-4-(N-methyl-2-phenylethyl))

38 propanilido) piperidine);

p. 15 SB 5719

```
1
         (8)
              Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-
 2
    piperidinyl] -N-phenylpropanamide);
         (9) Benzethidine;
 3
         (10) Betacetylmethadol;
 4
                  Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
 5
 6
    piperidinyl] -N-phenylpropanamide);
7
         (12) Beta-hydroxy-3-methylfentanyl, some trade or other names:
    N-[1-(2-hydrox-2-phenethyl)-3-methyl-4-piperidinyl]-N-
 8
    phenylpropanamide;
9
10
         (13) Betameprodine;
11
         (14) Betamethadol;
12
         (15) Betaprodine;
13
         (16) Clonitazene;
14
         (17) Dextromoramide;
15
         (18) Diampromide;
16
         (19) Diethylthiambutene;
17
         (20) Difenoxin;
         (21) Dimenoxadol;
18
19
         (22) Dimepheptanol;
         (23) Dimethylthiambutene;
20
         (24) Dioxaphetyl butyrate;
21
22
         (25) Dipipanone;
23
         (26) Ethylmethylthiambutene;
24
         (27) Etonitazene;
25
         (28) Etoxeridine;
26
         (29) Furethidine;
27
         (30) Hydroxypethidine;
28
         (31) Ketobemidone;
29
         (32) Levomoramide;
30
         (33) Levophenacylmorphan;
31
         (34)
                   3-Methylfentanyl
                                           (N-[3-methyl-1-(2-phenylethyl)-4-
32
    piperidyl]-N-phenylprop anamide);
33
                3-Methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-
         (35)
    piperidinyl]-N-phenylpropanamide);
34
35
         (36) Morpheridine;
         (37) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
36
37
         (38) Noracymethadol;
38
         (39) Norlevorphanol;
39
         (40) Normethadone;
40
         (41) Norpipanone;
```

p. 16 SB 5719

```
1
         (42)
                   Para-fluorofentanyl
                                              (N-(4-fluorophenyl)-N-[1-(2-
    phenethyl)-4-piperidinyl] propanamide);
2
         (43) PEPAP(1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
 3
 4
         (44) Phenadoxone;
         (45) Phenampromide;
 5
 6
         (46) Phenomorphan;
7
         (47) Phenoperidine;
         (48) Piritramide;
8
         (49) Proheptazine;
9
10
         (50) Properidine;
         (51) Propiram;
11
12
         (52) Racemoramide;
13
         (53) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-
14
     ((propanaminde)) propanamide);
15
         (54) Tilidine;
16
         (55) Trimeperidine.
17
         (b) Opium derivatives. Unless specifically excepted or unless
    listed in another schedule, any of the following opium derivatives,
18
    including their salts, isomers, and salts of isomers whenever the
19
    existence of those salts, isomers, and salts of isomers is possible
20
    within the specific chemical designation:
21
22
         (1) Acetorphine;
23
         (2) Acetyldihydrocodeine;
24
         (3) Benzylmorphine;
25
         (4) Codeine methylbromide;
26
         (5) Codeine-N-Oxide;
27
         (6) Cyprenorphine;
28
         (7) Desomorphine;
29
         (8) Dihydromorphine;
30
         (9) Drotebanol;
31
         (10) Etorphine, except hydrochloride salt;
32
         (11) Heroin;
33
         (12) Hydromorphinol;
34
         (13) Methyldesorphine;
         (14) Methyldihydromorphine;
35
36
         (15) Morphine methylbromide;
37
         (16) Morphine methylsulfonate;
         (17) Morphine-N-Oxide;
38
39
         (18) Myrophine;
40
         (19) Nicocodeine;
```

p. 17 SB 5719

```
1 (20) Nicomorphine;
```

- 2 (21) Normorphine;
- 3 (22) Pholcodine;
- 4 (23) Thebacon.
- (c) Hallucinogenic substances. Unless specifically excepted or 5 6 unless listed in another schedule, any material, compound, mixture, 7 preparation which contains any quantity of the following hallucinogenic substances, including their salts, isomers, and salts 8 of isomers whenever the existence of those salts, isomers, and salts 9 of isomers is possible within the specific chemical designation. For 10 the purposes of this subsection only, the term "isomer" includes the 11 12 optical, position, and geometric isomers:
- 13 (1) Alpha-ethyltryptamine: Some trade or other names: 14 Etryptamine; monase; a-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) 15 indole; a-ET; and AET;
- 16 (2) 4-bromo-2,5-dimethoxy-amphetamine: Some trade or other names: 17 4-bromo-2,5-dimethoxy-a-methylphenethylamine; 4-bromo-2,5-DMA;
- 18 (3) 4-bromo-2,5-dimethoxyphenethylamine: Some trade or other 19 names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl 20 DOB; 2C-B, nexus;
- 21 (4) 2,5-dimethoxyamphetamine: Some trade or other names: 2,5-22 dimethoxy-a-methylphenethylamine; 2,5-DMA;
- 23 (5) 2,5-dimethoxy-4-ethylamphetamine (DOET);
- 24 (6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine: Other name: 25 2C-T-7;
- 26 (7) 4-methoxyamphetamine: Some trade or other names: 4-methoxy-a-27 methylphenethylamine; paramethoxyamphetamine, PMA;
 - (8) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 29 (9) 4-methyl-2,5-dimethoxy-amphetamine: Some trade and other 30 names: 4-methyl-2,5-dimethoxy-a-methylphenethylamine; "DOM"; and "STP";
- 32 (10) 3,4-methylenedioxy amphetamine;
- 33 (11) 3,4-methylenedioxymethamphetamine (MDMA);
- 34 (12) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-35 ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, 36 MDE, MDEA;
- 37 (13) N-hydroxy-3,4-methylenedioxyamphetamine also known as 38 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine,N-hydroxy
- 39 MDA;

40 (14) 3,4,5-trimethoxy amphetamine;

p. 18 SB 5719

```
1 (15) Alpha-methyltryptamine: Other name: AMT;
```

- 2 (16) Bufotenine: Some trade or other names: 3-(beta-
- 3 Dimethylaminoethyl)-5-hydroxindole; 3-(2-dimethylaminoethyl)-5-
- 4 indolol; N, N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine;
- 5 mappine;
- 6 (17) Diethyltryptamine: Some trade or other names: N,N7 Diethyltryptamine; DET;
- 8 (18) Dimethyltryptamine: Some trade or other names: DMT;
- 9 (19) 5-methoxy-N, N-diisopropyltryptamine: Other name: 5-MeO-DIPT;
- 10 (20) Ibogaine: Some trade or other names: 7-Ethyl-6,6
- 11 beta, 7, 8, 9, 10, 12, 13, -octahydro-2-methoxy-6, 9-methano-5H-pyndo (1', 2'
- 12 1,2) azepino (5,4-b) indole; Tabernanthe iboga;
- 13 (21) Lysergic acid diethylamide;
- 14 (22) Marihuana or marijuana;
- 15 (23) Mescaline;
- 16 (24) Parahexyl-7374: Some trade or other names: 3-Hexyl-1-
- 17 hydroxy-7, 8, 9, 10-tetrahydro-6, 6, 9-trimethyl-6H-
- 18 dibenzo[b,d]pyran; synhexyl;
- 19 (25) Peyote, meaning all parts of the plant presently classified
- 20 botanically as Lophophora Williamsii Lemaire, whether growing or not,
- 21 the seeds thereof, any extract from any part of such plant, and every
- 22 compound, manufacture, salts, derivative, mixture, or preparation of
- 23 such plant, its seeds, or extracts; (interprets 21 U.S.C. Sec. 812
- 24 (c), Schedule I (c)(12));
- 25 (26) N-ethyl-3-piperidyl benzilate;
- 26 (27) N-methyl-3-piperidyl benzilate;
- 27 (28) Psilocybin;
- 28 (29) Psilocyn;
- 29 (30) (i) Tetrahydrocannabinols, meaning tetrahydrocannabinols
- 30 naturally contained in a plant of the ((genus)) <u>genera</u> Cannabis
- 31 (((cannabis plant))), as well as synthetic equivalents of the
- 32 substances contained in the plant, or in the resinous extractives of
- 33 <u>the genera</u> Cannabis, ((species,)) and/or synthetic substances,
- 34 derivatives, and their isomers with similar chemical structure and
- 35 pharmacological activity such as the following:
- 36 $((\frac{(i)}{(i)}))$ (A) 1 cis or trans tetrahydrocannabinol, and their
- 37 optical isomers, excluding tetrahydrocannabinol in sesame oil and
- 38 encapsulated in a soft gelatin capsule in a drug product approved by
- 39 the United States Food and Drug Administration;

p. 19 SB 5719

- 1 ((((ii)))) (B) 6 cis or trans tetrahydrocannabinol, and their 2 optical isomers;
- 3 (((iii))) (C) 3,4 cis or trans tetrahydrocannabinol, and its optical isomers; or
 - $((\frac{(iv)}{(iv)}))$ (D) That is chemically synthesized and either:
- 6 $((\frac{1}{2}))$ (I) Has been demonstrated to have binding activity at one or more cannabinoid receptors; or
- 8 (((b))) <u>(II)</u> Is a chemical analog or isomer of a compound that 9 has been demonstrated to have binding activity at one or more 10 cannabinoid receptors;
- 11 (Since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions covered.)
- (ii) Hemp, as defined in section 2 of this act, and industrial hemp, as defined in chapter 15.120 RCW, are excepted from the categories of controlled substances identified under this section;
 - (31) Ethylamine analog of phencyclidine: Some trade or other names: N-ethyl-1phenylcyclohexalymine, (1-phenylcyclohexal) ethylamine; N-(1-phenylcyclohexyl) ethylamine; cyclohexamine; PCE;
- 20 (32) Pyrrolidine analog of phencyclidine: Some trade or other 21 names: 1-(1-phencyclohexyl)pyrrolidine; PCPy; PHP;
- 22 (33) Thiophene analog of phencyclidine: Some trade or other 23 names: 1-(1-[2-thenyl]-cyclohexly)-pipendine; 2-thienylanalog of 24 phencyclidine; TPCP; TCP;
- 25 (34) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine: A trade or other 26 name is TCPy.
 - (d) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.
 - (1) Gamma-hydroxybutyric acid: Some other names include GHB; gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate;
 - (2) Mecloqualone;
 - (3) Methaqualone.

17

18

19

27

28

29

30 31

32

33

34

3536

3738

39 (e) Stimulants. Unless specifically excepted or unless listed in 40 another schedule, any material, compound, mixture, or preparation

p. 20 SB 5719

- which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:
 - (1) Aminorex: Some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4, 5-dihydro-5-phenly-2-oxazolamine;
 - (2) N-Benzylpiperazine: Some other names: BZP,1-benzylpiperazine;
- 7 (3) Cathinone, also known as 2-amino-1-phenyl-1-propanone, 8 alpha-aminopropiophenone, 2-aminopropiophenone and norephedrone;
 - (4) Fenethylline;

5

6

9

- 10 (5) Methcathinone: Some other names: 2-(methylamino)-11 propiophenone; alpha-(methylamino)propiophenone; 2-(methylamino)-1-12 phenylpropan-1-one; alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone; methylcathinone; 13 AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and 14 salts of optical isomers; 15
- 16 (6) (+-)cis-4-methylaminorex ((+-)cis-4,5-dihydro-4-methyl-5-17 phenyl-2-oxazolamine);
- 18 (7) N-ethylamphetamine;
- 19 (8) N,N-dimethylamphetamine: Some trade or other names: N,N-20 alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenoethylene.
- 21 The controlled substances in this section may be added, 22 rescheduled, or deleted as provided for in RCW 69.50.201.
- NEW SECTION. Sec. 16. The following acts or parts of acts, as now existing or hereafter amended, are each repealed, effective January 1, 2020:
- 26 (1) RCW 15.120.005 (Intent) and 2016 sp.s. c 11 s 1;
- 27 (2) RCW 15.120.010 (Definitions) and 2016 sp.s. c 11 s 2;
- 28 (3) RCW 15.120.020 (Industrial hemp—Agricultural product— 29 Exclusively as part of industrial hemp research program) and 2016 30 sp.s. c 11 s 3;
- 31 (4) RCW 15.120.030 (Rule-making authority) and 2016 sp.s. c 11 s 32 4;
- 33 (5) RCW 15.120.035 (Rule-making authority—Monetary penalties, 34 license suspension or forfeiture, other sanctions—Rules to be 35 consistent with section 7606 of federal agricultural act of 2014) and 36 2017 c 317 s 10;

p. 21 SB 5719

1 (6) RCW 15.120.040 (Industrial hemp research program—Established 2 —Licensure—Seed certification program—Permission/waiver from 3 appropriate federal entity) and 2016 sp.s. c 11 s 5;

4

5

6

- (7) RCW 15.120.050 (Application form—Fee—Licensure—Renewal—Record of license forwarded to county sheriff—Public disclosure exemption) and 2016 sp.s. c 11 s 6; and
- 7 (8) RCW 15.120.060 (Sales and transfers of industrial hemp 8 produced for processing—Department and state liquor and cannabis 9 board to study feasibility and practicality of implementing 10 legislatively authorized regulatory framework) and 2017 c 317 s 9.
- NEW SECTION. Sec. 17. The sum of three hundred thousand dollars, or as much thereof as may be necessary, is appropriated for the 2019-2021 biennium, from the general fund to the department of agriculture for the purposes of this act.
- NEW SECTION. Sec. 18. Sections 1 through 12 of this act constitute a new chapter in Title 15 RCW.
- NEW SECTION. Sec. 19. This act is necessary for the immediate preservation of the public peace, health, or safety, or support of the state government and its existing public institutions, and takes effect immediately.

--- END ---

p. 22 SB 5719